<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470027</url>
  </required_header>
  <id_info>
    <org_study_id>1109011912</org_study_id>
    <secondary_id>1R21AG041509</secondary_id>
    <nct_id>NCT01470027</nct_id>
  </id_info>
  <brief_title>N-Acetylcysteine for Neuroprotection in Parkinson's Disease</brief_title>
  <acronym>NAC for PD</acronym>
  <official_title>N-Acetylcysteine for Neuroprotection in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this developmental/exploratory study is to use noninvasive proton
      magnetic resonance spectroscopy (1H MRS) to assess (a) whether brain levels of the
      antioxidant glutathione (GSH) are decreased in vivo, as has been found in postmortem brain,
      in 30 patients with Parkinson's disease (PD) compared to matched controls; (b) whether GSH
      levels in PD brain increase significantly following 30 days of daily supplementation with
      1800mg or 3600mg of N-acetylcysteine (NAC) compared to placebo and to baseline, and (c)
      whether any such increases in brain GSH would be dose-dependent and be associated with a
      change in the participants' oxidative stress profiles. In addition, a clinical assessment
      battery, including quantitative tests of motor function, will be performed to investigate
      potential associations between the NAC intervention, brain GSH levels, oxidative stress
      markers, and clinical presentation. If successful, this study will represent the first
      objective documentation of whether there is a GSH deficit in living PD brain that dietary NAC
      supplementation can mitigate, thereby providing a compelling justification for investigating
      such neuroprotective strategies in larger controlled clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is a neurodegenerative disorder in which deficits of the primary
      intracellular antioxidant, glutathione (GSH), are postulated to mediate increased oxidative
      stress and mitochondrial dysfunction in the pathogenic cascade leading up to the loss of
      nigrostriatal dopaminergic neurons that is the hallmark of the disorder. Therefore, there is
      currently great interest in treatment strategies that can maintain, restore and/or elevate
      intracellular GSH levels. However, GSH does not readily cross the blood-brain barrier or the
      membranes of most cells, including neurons, so that direct dietary supplementation of the
      antioxidant has not proved viable in increasing its intracellular concentration. On the other
      hand, since the bioavailability of cysteine, which does cross both the blood-brain barrier
      and most cell membranes, is rate-limiting in the GSH synthesis pathway, this amino acid and
      its non-toxic derivatives, such as N-acetylcysteine (NAC), are being investigated as
      potential precursors that can be supplied through dietary means to spur in situ synthesis and
      elevation of brain GSH. The overall objective of this Exploratory/Developmental (R21) study
      is to use noninvasive proton magnetic resonance spectroscopy (1H MRS) to determine (a)
      whether levels of GSH are decreased in vivo in the brain of 30 patients with Parkinson's
      disease (PD) compared to matched controls, as has been found in postmortem brain; (b) whether
      GSH levels in PD brain increase significantly following 30 days of daily supplementation with
      1800mg or 3600mg of NAC compared to baseline and placebo, and (c) whether any such increases
      in brain GSH would be dose-dependent and be associated with a change in the participants'
      oxidative stress profiles. Additionally, a clinical assessment battery, including
      quantitative tests of motor function, will be performed to investigate potential associations
      between the NAC intervention, brain GSH levels, oxidative stress markers, and clinical
      presentation. If successful, this study will represent the first objective documentation of
      whether there is a GSH deficit in living PD brain that dietary NAC supplementation can
      mitigate, thereby providing a compelling justification for investigating such neuroprotective
      strategies in larger controlled clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy</measure>
    <time_frame>at baseline and 4 weeks after intervention start</time_frame>
    <description>In vivo brain GSH measured with 1H MRS in the unmedicated patients with idiopathic PD and in sex- and age-matched healthy controls prior to and following 4 weeks supplementation with either placebo, 1800mg/day or 3600 mg/day of NAC. Striatal and occipital cortex glutathione levels as measured in vivo by 1H MRS at baseline and following 4 weeks of treatment with placebo, 1800mg NAC/day and 3600mg NAC/day.
The area under the GSH spectral peak was obtained by frequency-domain fitting of the GSH resonance in the edited spectrum to a pseudo-Voigt lineshape function using a robust and highly optimized public-domain Levenberg-Marquardt nonlinear least-squares minimization routine. The resulting peak areas were then expressed as ratios relative to the synchronously acquired and similarly fitted unsuppressed voxel water signal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) Parts I-V (Total Score Reported)</measure>
    <time_frame>at baseline and 4 weeks after intervention start</time_frame>
    <description>The UPDRS is considered the gold standard for determining disease severity and progression in patients with Parkinson's disease. It consists of the following five elements:
Evaluation of mentation, behavior and mood.
Self evaluation of the activities of daily living (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, etc.
Motor evaluation by a clinician.
Hoehn and Yahr scale (Hoehn 1967) for the description of the overall disease severity in PD with 8 stages.
Schwab and England activities of daily living scale (Schwab and England 1969) for the estimation of the general abilities in PD patients. The Schwab and England ADL scale is graduated in 10% steps with 100% indicating complete independence and 0% indicating an individual in whom the vegetative functions are completely impaired.
A total of 199 points are possible for UPDRS, with 199 representing the worst disability and 0 no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Examination (MMSE)</measure>
    <time_frame>at baseline and 4 weeks after intervention start</time_frame>
    <description>The MMSE is a brief questionnaire-based test that is used to screen for cognitive impairment. Domains tested are orientation to time and place, registration, attention and calculation, recall, language, repetition and complex commands. Scores lower than 25/30 points indicate mild (21-24 points), moderate (10-20 points) or severe (&lt;10 points) cognitive impairment, but scores may need to be corrected for educational attainment, age and interfering impairments such as motor deficits that affect drawing skills.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D)</measure>
    <time_frame>at baseline and 4 weeks after intervention start</time_frame>
    <description>The Hamilton Depression Rating Scale (HAM-D) is a 21-item instrument designed to measure the severity of illness in adults already diagnosed as having depression. The Hamilton Depression Rating Scale (HAM-D) has proven useful for many years as a way of determining a patient's level of depression before, during, and after treatment. It is clinician-administered and requires 15 to 20 minutes complete the interview and score the results. Although the HAM-D form lists 21 items, the scoring is based on the first 17. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2.
The minimum score is 0 and maximum score is 50. The scale has been widely used in clinical practice and become a standard in pharmaceutical trials.
HAM-D Scoring Instructions are following:
0-7 = Normal; 8-13 = Mild Depression; 14-18 = Moderate Depression; 19-22 = Severe Depression;
≥ 23 = Very Severe Depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-Hole Peg Board Test (9-HPT)</measure>
    <time_frame>at baseline and 4 weeks after intervention start</time_frame>
    <description>The 9-HPT is a standardized, quantitative timed test of upper extremity motor function. Individuals are asked to place and remove nine pegs, one at a time, from nine holes in a board as quickly as possible. The task is performed twice with the dominant and twice with the non-dominant hand, and the average time to complete the task once is calculated for each hand. The 9-HPT has a high inter- and intra-rater reliability, is validated and is sensitive to detect minor impairments of hand function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-Meter Walk Test</measure>
    <time_frame>at baseline and 4 weeks after intervention start</time_frame>
    <description>The 10-meter walk test is a standardized, quantitative timed test of lower body motor function. The maximal gait speed is measured during a 10-meter walk. The task will be performed three times and the average time to complete the task once will be recorded. The 10-meter walk test is a reliable and sensitive measure of gait function in elderly individuals and PD patients.
Cut-off values:
&lt; 0.4 m/s more likely to be household ambulators; 0.4 - 0.8 m/s limited community ambulators; &gt; 0.8 m/s community ambulators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory</measure>
    <time_frame>at baseline and 4 weeks after intervention start</time_frame>
    <description>The Beck Anxiety Inventory (BAI) is a clinician-administered and validated instrument to discriminate anxiety from depression. The standardized BAI cutoffs are:
0-9: minimal anxiety; 10-16: mild anxiety; 17-29: moderate anxiety; 30-63: severe anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Quality of Life Questionnaire (PDQLQ)</measure>
    <time_frame>at baseline and 4 weeks after intervention start</time_frame>
    <description>The Parkinson's Disease Quality of Life Questionnaire is a self completion PRO designed to address aspects of functioning and well-being for those affected by Parkinson's disease.
The Parkinson's Disease Quality of Life Questionnaire is coded on a scale of 0 to 185, with 185 indicating perfect health and 0 indicating very poor health.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine 1800mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-acetylcysteine 1800mg/day for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine 3600mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-acetylcysteine 3600mg daily for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo effervescent tablets daily for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>900mg NAC effervescent tablets</description>
    <arm_group_label>N-acetylcysteine 1800mg</arm_group_label>
    <arm_group_label>N-acetylcysteine 3600mg</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>effervescent tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic PD according to the United Kingdom Parkinson's Disease Society
             Brain Bank criteria (UKPDSBB) criteria (only for PD group

          -  Age 50 to 75 years

          -  Able to give informed consent for study participation

          -  Not on any medication for PD (anticholinergic agents allowed)

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Unable to undergo a brain MRI

          -  PD duration ≥15 years

          -  Receiving dopamine receptor blocking agents, including typical neuroleptics,
             prochlorperazine, and metoclopramide

          -  Diagnosis of major depression or other axis I psychopathology

          -  Modified Mini-Mental Status Exam (MMSE) ≤ 24/30

          -  Diagnosis of chronic or persistent illnesses that could affect oxidative stress
             status, such as diabetes or congestive heart failure

          -  Significant concomitant medical disease limiting life expectancy to less than 12
             months from study inclusion

          -  Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis or
             other neurodegenerative diseases such as Alzheimer's disease or ALS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dikoma C. Shungu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <results_first_submitted>November 6, 2017</results_first_submitted>
  <results_first_submitted_qc>March 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2018</results_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>Dikoma C. Shungu</investigator_full_name>
    <investigator_title>Professor of Physics in Radiology</investigator_title>
  </responsible_party>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>antioxidant</keyword>
  <keyword>glutathione</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment for this pilot clinical study started in March 2012, as the end of the study in August 2016, 23 of 30 PD patients and 27 of 30 healthy volunteers (HV) subjects - a total 50- had participated in the study. All subjects enrolled at the Weill Cornell Parkinson’s Disease and Movement Disorders Institute, led by the study neurologist.</recruitment_details>
      <pre_assignment_details>A total of 50 subjects enrolled into the study (23 PD patients and 27 HV subjects). Only 21 patients with PD and 26 HV subjects underwent the baseline assessments. Two PD patients and 1 HV subject were excluded from the study before assignment to groups. All exclusion were unrelated to the study protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine 1800mg</title>
          <description>N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="P2">
          <title>N-acetylcysteine 3600mg</title>
          <description>N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
          <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="B2">
          <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
          <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="B3">
          <title>Placebo -Parkinson's Patient</title>
          <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
        </group>
        <group group_id="B4">
          <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
          <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="B5">
          <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
          <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="B6">
          <title>Placebo -Healthy Volunteer</title>
          <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.000" spread="5.259"/>
                    <measurement group_id="B2" value="61.714" spread="6.264"/>
                    <measurement group_id="B3" value="62.429" spread="2.820"/>
                    <measurement group_id="B4" value="64.222" spread="7.807"/>
                    <measurement group_id="B5" value="56.625" spread="5.927"/>
                    <measurement group_id="B6" value="59.778" spread="5.995"/>
                    <measurement group_id="B7" value="60.809" spread="6.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy</title>
        <description>In vivo brain GSH measured with 1H MRS in the unmedicated patients with idiopathic PD and in sex- and age-matched healthy controls prior to and following 4 weeks supplementation with either placebo, 1800mg/day or 3600 mg/day of NAC. Striatal and occipital cortex glutathione levels as measured in vivo by 1H MRS at baseline and following 4 weeks of treatment with placebo, 1800mg NAC/day and 3600mg NAC/day.
The area under the GSH spectral peak was obtained by frequency-domain fitting of the GSH resonance in the edited spectrum to a pseudo-Voigt lineshape function using a robust and highly optimized public-domain Levenberg–Marquardt nonlinear least-squares minimization routine. The resulting peak areas were then expressed as ratios relative to the synchronously acquired and similarly fitted unsuppressed voxel water signal.</description>
        <time_frame>at baseline and 4 weeks after intervention start</time_frame>
        <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for brain GSH levels because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment GSH values were available only for 43 subjects, whose data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo -Parkinson's Patient</title>
            <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
          <group group_id="O4">
            <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O5">
            <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O6">
            <title>Placebo -Healthy Volunteer</title>
            <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy</title>
          <description>In vivo brain GSH measured with 1H MRS in the unmedicated patients with idiopathic PD and in sex- and age-matched healthy controls prior to and following 4 weeks supplementation with either placebo, 1800mg/day or 3600 mg/day of NAC. Striatal and occipital cortex glutathione levels as measured in vivo by 1H MRS at baseline and following 4 weeks of treatment with placebo, 1800mg NAC/day and 3600mg NAC/day.
The area under the GSH spectral peak was obtained by frequency-domain fitting of the GSH resonance in the edited spectrum to a pseudo-Voigt lineshape function using a robust and highly optimized public-domain Levenberg–Marquardt nonlinear least-squares minimization routine. The resulting peak areas were then expressed as ratios relative to the synchronously acquired and similarly fitted unsuppressed voxel water signal.</description>
          <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for brain GSH levels because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment GSH values were available only for 43 subjects, whose data were included in the analysis.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ( In Striatum)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.422" spread="0.7371"/>
                    <measurement group_id="O2" value="3.334" spread="0.8754"/>
                    <measurement group_id="O3" value="3.745" spread="1.418"/>
                    <measurement group_id="O4" value="4.282" spread="0.946"/>
                    <measurement group_id="O5" value="4.415" spread="0.928"/>
                    <measurement group_id="O6" value="3.901" spread="0.9698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start ( In Striatum)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.404" spread="0.7684"/>
                    <measurement group_id="O2" value="3.473" spread="1.010"/>
                    <measurement group_id="O3" value="4.105" spread="1.292"/>
                    <measurement group_id="O4" value="4.843" spread="0.9884"/>
                    <measurement group_id="O5" value="3.900" spread="0.724"/>
                    <measurement group_id="O6" value="3.831" spread="0.8106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ( In Occipital)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.743" spread="0.4867"/>
                    <measurement group_id="O2" value="1.938" spread="0.3415"/>
                    <measurement group_id="O3" value="1.799" spread="0.4608"/>
                    <measurement group_id="O4" value="2.190" spread="0.5077"/>
                    <measurement group_id="O5" value="2.007" spread="0.395"/>
                    <measurement group_id="O6" value="2.001" spread="0.4755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start ( In Occipital)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.962" spread="0.5012"/>
                    <measurement group_id="O2" value="2.108" spread="0.3788"/>
                    <measurement group_id="O3" value="2.118" spread="0.422"/>
                    <measurement group_id="O4" value="2.161" spread="0.4027"/>
                    <measurement group_id="O5" value="1.990" spread="0.3344"/>
                    <measurement group_id="O6" value="2.298" spread="0.7663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unified Parkinson's Disease Rating Scale (UPDRS) Parts I-V (Total Score Reported)</title>
        <description>The UPDRS is considered the gold standard for determining disease severity and progression in patients with Parkinson’s disease. It consists of the following five elements:
Evaluation of mentation, behavior and mood.
Self evaluation of the activities of daily living (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, etc.
Motor evaluation by a clinician.
Hoehn and Yahr scale (Hoehn 1967) for the description of the overall disease severity in PD with 8 stages.
Schwab and England activities of daily living scale (Schwab and England 1969) for the estimation of the general abilities in PD patients. The Schwab and England ADL scale is graduated in 10% steps with 100% indicating complete independence and 0% indicating an individual in whom the vegetative functions are completely impaired.
A total of 199 points are possible for UPDRS, with 199 representing the worst disability and 0 no disability.</description>
        <time_frame>at baseline and 4 weeks after intervention start</time_frame>
        <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for Unified Parkinson's Disease Rating Scale (UPDRS) because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment UPDRS were available only for 40 subjects, whose data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo -Parkinson's Patient</title>
            <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
          <group group_id="O4">
            <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O5">
            <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O6">
            <title>Placebo -Healthy Volunteer</title>
            <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Parts I-V (Total Score Reported)</title>
          <description>The UPDRS is considered the gold standard for determining disease severity and progression in patients with Parkinson’s disease. It consists of the following five elements:
Evaluation of mentation, behavior and mood.
Self evaluation of the activities of daily living (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, etc.
Motor evaluation by a clinician.
Hoehn and Yahr scale (Hoehn 1967) for the description of the overall disease severity in PD with 8 stages.
Schwab and England activities of daily living scale (Schwab and England 1969) for the estimation of the general abilities in PD patients. The Schwab and England ADL scale is graduated in 10% steps with 100% indicating complete independence and 0% indicating an individual in whom the vegetative functions are completely impaired.
A total of 199 points are possible for UPDRS, with 199 representing the worst disability and 0 no disability.</description>
          <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for Unified Parkinson's Disease Rating Scale (UPDRS) because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment UPDRS were available only for 40 subjects, whose data were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.286" spread="15.152"/>
                    <measurement group_id="O2" value="31.500" spread="10.782"/>
                    <measurement group_id="O3" value="16.714" spread="4.923"/>
                    <measurement group_id="O4" value="1.000" spread="2.071"/>
                    <measurement group_id="O5" value="4.500" spread="2.082"/>
                    <measurement group_id="O6" value="3.143" spread="5.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.857" spread="16.547"/>
                    <measurement group_id="O2" value="24.249" spread="16.547"/>
                    <measurement group_id="O3" value="13.857" spread="6.817"/>
                    <measurement group_id="O4" value="0.600" spread="1.342"/>
                    <measurement group_id="O5" value="3.000" spread="2.160"/>
                    <measurement group_id="O6" value="1.857" spread="3.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini Mental State Examination (MMSE)</title>
        <description>The MMSE is a brief questionnaire-based test that is used to screen for cognitive impairment. Domains tested are orientation to time and place, registration, attention and calculation, recall, language, repetition and complex commands. Scores lower than 25/30 points indicate mild (21-24 points), moderate (10-20 points) or severe (&lt;10 points) cognitive impairment, but scores may need to be corrected for educational attainment, age and interfering impairments such as motor deficits that affect drawing skills.</description>
        <time_frame>at baseline and 4 weeks after intervention start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo -Parkinson's Patient</title>
            <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
          <group group_id="O4">
            <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O5">
            <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O6">
            <title>Placebo -Healthy Volunteer</title>
            <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mini Mental State Examination (MMSE)</title>
          <description>The MMSE is a brief questionnaire-based test that is used to screen for cognitive impairment. Domains tested are orientation to time and place, registration, attention and calculation, recall, language, repetition and complex commands. Scores lower than 25/30 points indicate mild (21-24 points), moderate (10-20 points) or severe (&lt;10 points) cognitive impairment, but scores may need to be corrected for educational attainment, age and interfering impairments such as motor deficits that affect drawing skills.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.571" spread="0.5345"/>
                    <measurement group_id="O2" value="29.857" spread="0.3780"/>
                    <measurement group_id="O3" value="29.571" spread="0.787"/>
                    <measurement group_id="O4" value="29.778" spread="0.667"/>
                    <measurement group_id="O5" value="29.625" spread="0.518"/>
                    <measurement group_id="O6" value="30.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.667" spread="0.516"/>
                    <measurement group_id="O2" value="29.714" spread="0.489"/>
                    <measurement group_id="O3" value="30.000" spread="0.000"/>
                    <measurement group_id="O4" value="29.857" spread="0.378"/>
                    <measurement group_id="O5" value="30.000" spread="0.000"/>
                    <measurement group_id="O6" value="29.750" spread="0.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Rating Scale (HAM-D)</title>
        <description>The Hamilton Depression Rating Scale (HAM-D) is a 21-item instrument designed to measure the severity of illness in adults already diagnosed as having depression. The Hamilton Depression Rating Scale (HAM-D) has proven useful for many years as a way of determining a patient’s level of depression before, during, and after treatment. It is clinician-administered and requires 15 to 20 minutes complete the interview and score the results. Although the HAM-D form lists 21 items, the scoring is based on the first 17. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2.
The minimum score is 0 and maximum score is 50. The scale has been widely used in clinical practice and become a standard in pharmaceutical trials.
HAM-D Scoring Instructions are following:
0-7 = Normal; 8-13 = Mild Depression; 14-18 = Moderate Depression; 19-22 = Severe Depression;
≥ 23 = Very Severe Depression.</description>
        <time_frame>at baseline and 4 weeks after intervention start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo -Parkinson's Patient</title>
            <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
          <group group_id="O4">
            <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O5">
            <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O6">
            <title>Placebo -Healthy Volunteer</title>
            <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HAM-D)</title>
          <description>The Hamilton Depression Rating Scale (HAM-D) is a 21-item instrument designed to measure the severity of illness in adults already diagnosed as having depression. The Hamilton Depression Rating Scale (HAM-D) has proven useful for many years as a way of determining a patient’s level of depression before, during, and after treatment. It is clinician-administered and requires 15 to 20 minutes complete the interview and score the results. Although the HAM-D form lists 21 items, the scoring is based on the first 17. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2.
The minimum score is 0 and maximum score is 50. The scale has been widely used in clinical practice and become a standard in pharmaceutical trials.
HAM-D Scoring Instructions are following:
0-7 = Normal; 8-13 = Mild Depression; 14-18 = Moderate Depression; 19-22 = Severe Depression;
≥ 23 = Very Severe Depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.714" spread="2.430"/>
                    <measurement group_id="O2" value="3.571" spread="2.430"/>
                    <measurement group_id="O3" value="1.857" spread="1.951"/>
                    <measurement group_id="O4" value="2.222" spread="3.032"/>
                    <measurement group_id="O5" value="1.875" spread="1.807"/>
                    <measurement group_id="O6" value="1.889" spread="2.2608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.167" spread="3.869"/>
                    <measurement group_id="O2" value="3.857" spread="2.854"/>
                    <measurement group_id="O3" value="1.714" spread="1.976"/>
                    <measurement group_id="O4" value="1.286" spread="1.890"/>
                    <measurement group_id="O5" value="0.714" spread="1.113"/>
                    <measurement group_id="O6" value="1.222" spread="1.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9-Hole Peg Board Test (9-HPT)</title>
        <description>The 9-HPT is a standardized, quantitative timed test of upper extremity motor function. Individuals are asked to place and remove nine pegs, one at a time, from nine holes in a board as quickly as possible. The task is performed twice with the dominant and twice with the non-dominant hand, and the average time to complete the task once is calculated for each hand. The 9-HPT has a high inter- and intra-rater reliability, is validated and is sensitive to detect minor impairments of hand function.</description>
        <time_frame>at baseline and 4 weeks after intervention start</time_frame>
        <population>The measurement used for the 9-HPT is the average of time needed to complete the task with the dominant and non-dominant hand recorded in seconds. The presence of PD is expected to produce higher test times in seconds.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo -Parkinson's Patient</title>
            <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
          <group group_id="O4">
            <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O5">
            <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O6">
            <title>Placebo -Healthy Volunteer</title>
            <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
        </group_list>
        <measure>
          <title>9-Hole Peg Board Test (9-HPT)</title>
          <description>The 9-HPT is a standardized, quantitative timed test of upper extremity motor function. Individuals are asked to place and remove nine pegs, one at a time, from nine holes in a board as quickly as possible. The task is performed twice with the dominant and twice with the non-dominant hand, and the average time to complete the task once is calculated for each hand. The 9-HPT has a high inter- and intra-rater reliability, is validated and is sensitive to detect minor impairments of hand function.</description>
          <population>The measurement used for the 9-HPT is the average of time needed to complete the task with the dominant and non-dominant hand recorded in seconds. The presence of PD is expected to produce higher test times in seconds.</population>
          <units>s (in seconds)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.026" spread="19.509"/>
                    <measurement group_id="O2" value="27.795" spread="5.660"/>
                    <measurement group_id="O3" value="28.694" spread="7.886"/>
                    <measurement group_id="O4" value="25.088" spread="4.489"/>
                    <measurement group_id="O5" value="24.593" spread="6.089"/>
                    <measurement group_id="O6" value="25.834" spread="4.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.756" spread="7.116"/>
                    <measurement group_id="O2" value="25.980" spread="6.231"/>
                    <measurement group_id="O3" value="28.084" spread="9.373"/>
                    <measurement group_id="O4" value="24.940" spread="2.995"/>
                    <measurement group_id="O5" value="22.511" spread="6.325"/>
                    <measurement group_id="O6" value="24.704" spread="4.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>10-Meter Walk Test</title>
        <description>The 10-meter walk test is a standardized, quantitative timed test of lower body motor function. The maximal gait speed is measured during a 10-meter walk. The task will be performed three times and the average time to complete the task once will be recorded. The 10-meter walk test is a reliable and sensitive measure of gait function in elderly individuals and PD patients.
Cut-off values:
&lt; 0.4 m/s more likely to be household ambulators; 0.4 - 0.8 m/s limited community ambulators; &gt; 0.8 m/s community ambulators.</description>
        <time_frame>at baseline and 4 weeks after intervention start</time_frame>
        <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for 10-Meter Walk Test because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment 10-Meter Walk Test score were available only for 46 subjects, whose data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo -Parkinson's Patient</title>
            <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
          <group group_id="O4">
            <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O5">
            <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O6">
            <title>Placebo -Healthy Volunteer</title>
            <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
        </group_list>
        <measure>
          <title>10-Meter Walk Test</title>
          <description>The 10-meter walk test is a standardized, quantitative timed test of lower body motor function. The maximal gait speed is measured during a 10-meter walk. The task will be performed three times and the average time to complete the task once will be recorded. The 10-meter walk test is a reliable and sensitive measure of gait function in elderly individuals and PD patients.
Cut-off values:
&lt; 0.4 m/s more likely to be household ambulators; 0.4 - 0.8 m/s limited community ambulators; &gt; 0.8 m/s community ambulators.</description>
          <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for 10-Meter Walk Test because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment 10-Meter Walk Test score were available only for 46 subjects, whose data were included in the analysis.</population>
          <units>m/s (meters per second)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.816" spread="1.820"/>
                    <measurement group_id="O2" value="7.289" spread="1.281"/>
                    <measurement group_id="O3" value="6.896" spread="0.907"/>
                    <measurement group_id="O4" value="7.253" spread="0.713"/>
                    <measurement group_id="O5" value="10.403" spread="6.380"/>
                    <measurement group_id="O6" value="7.141" spread="0.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.513" spread="7.136"/>
                    <measurement group_id="O2" value="7.434" spread="1.389"/>
                    <measurement group_id="O3" value="6.296" spread="0.929"/>
                    <measurement group_id="O4" value="7.279" spread="0.643"/>
                    <measurement group_id="O5" value="9.740" spread="5.958"/>
                    <measurement group_id="O6" value="6.893" spread="0.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Anxiety Inventory</title>
        <description>The Beck Anxiety Inventory (BAI) is a clinician-administered and validated instrument to discriminate anxiety from depression. The standardized BAI cutoffs are:
0–9: minimal anxiety; 10–16: mild anxiety; 17–29: moderate anxiety; 30–63: severe anxiety.</description>
        <time_frame>at baseline and 4 weeks after intervention start</time_frame>
        <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for Beck Anxiety Inventory (BAI) test because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment BAI scores were available only for 45 subjects, whose data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo -Parkinson's Patient</title>
            <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
          <group group_id="O4">
            <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O5">
            <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O6">
            <title>Placebo -Healthy Volunteer</title>
            <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Anxiety Inventory</title>
          <description>The Beck Anxiety Inventory (BAI) is a clinician-administered and validated instrument to discriminate anxiety from depression. The standardized BAI cutoffs are:
0–9: minimal anxiety; 10–16: mild anxiety; 17–29: moderate anxiety; 30–63: severe anxiety.</description>
          <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for Beck Anxiety Inventory (BAI) test because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment BAI scores were available only for 45 subjects, whose data were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.000" spread="6.782"/>
                    <measurement group_id="O2" value="9.000" spread="5.686"/>
                    <measurement group_id="O3" value="6.333" spread="5.046"/>
                    <measurement group_id="O4" value="3.778" spread="4.944"/>
                    <measurement group_id="O5" value="3.750" spread="5.365"/>
                    <measurement group_id="O6" value="2.625" spread="3.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" spread="2.450"/>
                    <measurement group_id="O2" value="8.286" spread="4.386"/>
                    <measurement group_id="O3" value="5.714" spread="5.438"/>
                    <measurement group_id="O4" value="2.429" spread="2.371"/>
                    <measurement group_id="O5" value="5.714" spread="5.345"/>
                    <measurement group_id="O6" value="4.333" spread="8.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson's Disease Quality of Life Questionnaire (PDQLQ)</title>
        <description>The Parkinson's Disease Quality of Life Questionnaire is a self completion PRO designed to address aspects of functioning and well-being for those affected by Parkinson’s disease.
The Parkinson's Disease Quality of Life Questionnaire is coded on a scale of 0 to 185, with 185 indicating perfect health and 0 indicating very poor health.</description>
        <time_frame>at baseline and 4 weeks after intervention start</time_frame>
        <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for PDQLQ because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment PDQLQ scores were available only for 43 subjects, whose data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
            <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo -Parkinson's Patient</title>
            <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
          <group group_id="O4">
            <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O5">
            <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
            <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
          </group>
          <group group_id="O6">
            <title>Placebo -Healthy Volunteer</title>
            <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinson's Disease Quality of Life Questionnaire (PDQLQ)</title>
          <description>The Parkinson's Disease Quality of Life Questionnaire is a self completion PRO designed to address aspects of functioning and well-being for those affected by Parkinson’s disease.
The Parkinson's Disease Quality of Life Questionnaire is coded on a scale of 0 to 185, with 185 indicating perfect health and 0 indicating very poor health.</description>
          <population>The number of participants in the Participant Flow module is different from the Overall Number of Participants for PDQLQ because of the total sample of 47 subjects enrolled in the study, baseline and post-treatment PDQLQ scores were available only for 43 subjects, whose data were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.333" spread="34.488"/>
                    <measurement group_id="O2" value="142.285" spread="14.739"/>
                    <measurement group_id="O3" value="159.833" spread="13.586"/>
                    <measurement group_id="O4" value="175.667" spread="19.526"/>
                    <measurement group_id="O5" value="171.625" spread="18.647"/>
                    <measurement group_id="O6" value="175.250" spread="14.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after intervention start</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.100" spread="45.081"/>
                    <measurement group_id="O2" value="135.571" spread="14.010"/>
                    <measurement group_id="O3" value="159.429" spread="17.634"/>
                    <measurement group_id="O4" value="177.833" spread="11.565"/>
                    <measurement group_id="O5" value="165.142" spread="17.601"/>
                    <measurement group_id="O6" value="181.750" spread="2.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (day 0) to 4 weeks after intervention start</time_frame>
      <group_list>
        <group group_id="E1">
          <title>N-acetylcysteine 1800mg - Parkinson's Patient</title>
          <description>Parkinson's patient
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="E2">
          <title>N-acetylcysteine 3600mg -Parkinson's Patient</title>
          <description>Parkinson's patient
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="E3">
          <title>Placebo -Parkinson's Patient</title>
          <description>Parkinson's patient
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
        </group>
        <group group_id="E4">
          <title>N-acetylcysteine 1800mg - Healthy Volunteer</title>
          <description>Healthy Volunteer
N-acetylcysteine 1800mg/day for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="E5">
          <title>N-acetylcysteine 3600mg -Healthy Volunteer</title>
          <description>Healthy Volunteer
N-acetylcysteine 3600mg daily for 30 days
N-acetylcysteine: 900mg NAC effervescent tablets</description>
        </group>
        <group group_id="E6">
          <title>Placebo -Healthy Volunteer</title>
          <description>Healthy Volunteer
Placebo effervescent tablets daily for 30 days
Placebo: effervescent tablets</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>puffy face, increased heart rate</sub_title>
                <description>Withdrew from study. Described &quot;hot flash inside head&quot;</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting, loss of appetite</sub_title>
                <description>Few days of nausea and vomiting, loss of appetite, no stomach pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache, neck pain, tiredness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Metallic taste, Occasional light-headed on standing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lightheaded after exercise, daytime napping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Shoulder and neck pain</sub_title>
                <description>Doctor think it is due to a rotatory cuff</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Incidental finding in MRI</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>left Acom aneurysm - intervention unwarranted due to small size</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Occasional skin itching</sub_title>
                <description>Occasional skin itching</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was limited by recruitment challenges related to identifying sufficient numbers of patients with PD who met all the eligibility criteria, especially with respect to medication status, and were willing to enter into the 4-week trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Dikoma C. Shungu, Professor of Physics in Radiology</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>2127462481</phone>
      <email>dcs7001@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

